Skip to main content

Advertisement

Table 1 Study population

From: Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial

  AL only AL + 0.25 mg/kg PQ AL + 0.40 mg/kg PQ
Asymptomatic parasite carriers (Study Phase A)
 Female (%) 51.6 52.0 53.4
 Age (years) 7.5 (4 – 10) 8 (5 – 10) 8 (4 – 10)
 Haemoglobin (g/dL) at enrolmenta 10.8 (10.2 – 11.4) 11.3 (10.7 – 11.9) 11.7 (11.2 – 12.2)
 Asexual parasite levels at enrolment (parasites/μL; Microscopy) 2,972.5 (1,147 – 6,865) 2,503 (939 – 5,798) 3,339 (874 – 7,358)
 Gametocyte prevalence (%) at enrolment (Microscopy) 17.7 32.0 20.5
 Gametocyte prevalence (%) at enrolment (QT-NASBA) 96.4 92.9 85.5
Asymptomatic gametocyte carriers (Study Phase B)
 Female (%) 43.1 46.0 42.9
 Age (years) 8 (5 – 11) 7 (6 – 11) 8 (6 – 11)
 Haemoglobin (g/dL) at enrolmenta 11.4 (11.1 – 11.8) 11.7 (11.4 – 12.1) 11.5 (11.1 – 11.9)
 Asexual parasite levels at enrolment (parasites/μL; Microscopy) 488 (226 – 1,670) 957 (248 – 3,004) 908.5 (198 – 2,297)
 Gametocyte prevalence (%) at screening (Microscopy) 100 100 100
 Gametocyte prevalence (%) at enrolment (Microscopy) 69.4 55.3 83.3
 Gametocyte prevalence (%) at enrolment (QT-NASBA) 95.9 93.7 100.0
 Gametocyte levels at enrolment (parasites/μL)b 17.3 (7.2 - 45.1) 18.6 (7.8 - 75.3) 16.6 (7.2 - 40.0)
  1. Means and 95 % confidence intervals are presented for haemoglobin levels at enrolment; medians and interquartile ranges are presented for parasite levels (asexual or sexual stages) and age. Study Phase A = presence of asexual parasites (1,000 - 200,000 parasites/μl) at screening as an inclusion criterion; Study Phase B = presence of patent gametocytes at screening as an inclusion criterion
  2. AL artemether-lumefantrine, PQ primaquine
  3. aMeasured by Hemocue photometer; similar values observed with full blood count assessment using venous samples
  4. bQuantified by qRT-PCR (only children with patent gametocytes on day 0 [N = 150] were included [100/150 were enrolled during Study Phase B]; see Methods)